RTP Mobile Logo
Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Lung Cancer
Released August 2012

A case–based roundtable discussion featuring the perspectives of Drs Thomas J Lynch Jr, Corey J Langer, Jyoti D Patel and Gregory J Riely. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is increasingly recognized as a heterogeneous group of neoplasms. Not long ago it was clinically sufficient to differentiate between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Now individualized treatment decisions are increasingly driven by genetic biomarkers in addition to histologic subtype and patient-specific characteristics. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists must be well informed of this increased understanding of the phenotypically unique subsets of lung cancer to enable customized treatment planning. To provide clinicians with therapeutic strategies for addressing the disparate needs of patients with lung cancer, the Rounds with the Investigators audio series employs an innovative, case-based approach that unites the perspectives of leading lung cancer investigators and community oncologists as they explore the intricacies of clinical decision-making. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Employ case-based learning to effectively implement evidence-based diagnostic and therapeutic approaches for patients with lung cancer.
    • Effectively utilize tumor histology in making evidence-based lung cancer treatment decisions.
    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions and other recently identified driver mutations — and the investigational and approved treatment options for patients with these biomarkers.
    • Individualize adjuvant chemotherapy for patients with early-stage NSCLC, with consideration of the efficacy and unique side-effect and tolerability profiles of guideline-endorsed regimens.
    • Evaluate the potential benefits of low-dose CT screening for appropriately selected individuals at high risk for the development of lung cancer.
    • Identify patients with metastatic NSCLC who may experience incremental benefit from maintenance biologic therapy and/or chemotherapy.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio MP3s, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/RWILung112/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LangerAdvisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Synta Pharmaceuticals Corp; Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Synta Pharmaceuticals Corp; Data and Safety Monitoring Committee: Amgen Inc; Paid Research: Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline. Dr LynchAdvisory Committee and Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Merck and Company Inc, SuperGen Inc; Board of Directors and Stock Ownership: Infinity Pharmaceuticals Inc. Dr PatelAdvisory Committee: Genentech BioOncology. Dr RielyConsulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Novartis Pharmaceuticals Corporation.

    COMMUNITY PANEL Drs Deutsch, Ferris, Rodriguez and Rupard had no real or apparent conflicts of interest to disclose. Dr GrabelskyPaid Research: Amgen Inc, Peregrine Pharmaceuticals Inc. Dr RaezSpeakers Bureau: Genentech BioOncology, Lilly USA LLC; Paid Research: Genentech BioOncology, Lilly USA LLC, Pfizer Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology and Lilly USA LLC.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2012
    Expiration date: August 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Lung Cancer
Released August 2012

A case–based roundtable discussion featuring the perspectives of Drs Thomas J Lynch Jr, Corey J Langer, Jyoti D Patel and Gregory J Riely. (Audio Content)

Read print: